進階篩選

Technical category
技術研發單位
    • 使用G72蛋白質與SLC7A11 mRNA作為生物標記來診斷阿茲海默氏症的方法

      Precision Health Ecosystem FutureTech 使用G72蛋白質與SLC7A11 mRNA作為生物標記來診斷阿茲海默氏症的方法

      The present technology provides a method for diagnosing Alzheimer's disease, including the following steps: detecting a blood sample taken from a human subject suspected of having Alzheimer's disease,the biomarker level is selected from G72 protein level, SLC7A11 mRNA expression level,a combination of the two,compared with a preset standard, wherein if the detected biomarker level in the blood sample is higher than the preset standard, the Individual humans are thought to have Alzheimer's disease.
    • 5D智慧城市─SmartES平台

      AI & IOT Application FutureTech 5D智慧城市─SmartES平台

      NCREE has originally developed 5D digital space—on the basis of 3D city modelsconnections of different kinds of sensors around the world— is an online to offline virtual space with a combination of rising 5G technology advantages. Collectingreorganizing various 3D cartographic data with Building Information Modeling (BIM), satellite imagery, UAV 3D modeling, LiDar point cloud data, etc., can increase the diversity of the buildinglandscape. 5D+5G smart city platform would accelerate the 5D smart city to become the digital twin of a real city.
    • 生物製造之癌症晶片應用於患者特異性用藥預測平台

      FutureTech 生物製造之癌症晶片應用於患者特異性用藥預測平台

      The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironmenttumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughputhigh-quality cell viability detectionbiomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification,tumor physiological environment for the upon goal.
    • The establishment of National Biobank Consortium of Taiwan (NBCT)

      Precision Health Ecosystem FutureTech The establishment of National Biobank Consortium of Taiwan (NBCT)

      This project will establish a National biobank consortium of Taiwan through the fund support from the government. The National Health Research Institutes will establish a Central Office for the collaboration works, which includes collecting the number of samples of the human biological database in each biobank that agreed to join the Consortium. All Alliance need to follow the same SOP for the collection processthe quality of the biosample. Adequateconsistent clinical data will also be established under the Information Security Management Treaty. Since the contents of the biobanks from different institute are quite different, we will be able to quickly establish a largecomprehensive biobank network.In line with the need of biotechnologypharmaceutical industries.
    • 可攜式液相層析質譜儀

      FutureTech 可攜式液相層析質譜儀

      We based on ion trap for mass filter so that ultra-high vacuum is not needed to reduce the weightsize. We took frequency scanning to increase our mass range by 10,000,000,000. We used LED as LC detector to reduce sizecost. Therefore, we not only made a portable device but also a device with many special advantages in technology. An advanced analytical lab can become mobile to easily reach anywhere which needs in-situreal-time analysis by our inventions.
    • 泌尿道上皮癌微型 RNA 篩檢套組

      FutureTech 泌尿道上皮癌微型 RNA 篩檢套組

      The screening kits were developed using miRNAs for high-risk populations for urothelial carcinoma (UC). Products 702703 are designed for chronic kidney diseasehemodialysis patients using urineblood samples, respectively. With high accuracyminimal invasiveness, the kits are intended to be used as a screeningregular monitoring of UC. If a test reveals a positive result, the patient then undergoes cystoscopic examination for further confirmation. Otherwise, the patent only needs to be monitored annually.